56P Simultaneous tissue and liquid next-generation sequencing after first-line EGFR tyrosine kinase inhibitors resistance in advanced non-small cell lung cancer

Y-T Lin,C-C Ho,W-H Hsu,W-Y Liao,C-Y Yang,K.T Tan,W Hsiao,J-Y Shih

doi:10.1016/j.annonc.2022.02.065

56P Simultaneous tissue and liquid next-generation sequencing after first-line EGFR tyrosine kinase inhibitors resistance in advanced non-small cell lung cancer

Y-T Lin, C-C Ho + Show 6 more

Open Access

https://doi.org/10.1016/j.annonc.2022.02.065

Copy DOI

Journal: Annals of oncology : official journal of the European Society for Medical Oncology	Publication Date: Apr 1, 2022
License type: elsevier-specific: oa user license

Affiliation: National Taiwan University, National Taiwan University Hospital, Genomics Research Center, Academia Sinica

#First-line EGFR Tyrosine Kinase Inhibitors #Second-generation EGFR Tyrosine Kinase Inhibitors + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

T790M testing is recommended after resistance to first or second-generation EGFR tyrosine kinase inhibitors (TKIs). However, the role of simultaneous tissue and liquid next-generation sequencing (NGS) after first-line EGFR TKI resistance is still unclear.

Full Text